Biodrugs

Papers
(The TQCC of Biodrugs is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Designer Exosomes: A New Platform for Biotechnology Therapeutics133
Therapeutic siRNA: State-of-the-Art and Future Perspectives101
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future62
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease60
Beyond Antibodies: The DARPin® Drug Platform55
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy50
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins45
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks45
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic42
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges36
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption36
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study34
Dengue Vaccines: An Update34
The Importance of Countering Biosimilar Disparagement and Misinformation34
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice32
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis31
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success30
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond30
Teserpaturev/G47Δ: First Approval28
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA27
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer27
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration26
The Immunotherapy Landscape in Renal Cell Carcinoma25
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study25
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering25
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin24
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants24
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities23
Targeted Therapies for Eosinophilic Gastrointestinal Disorders23
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis23
Monoclonal Antibody-Based Therapies for Myasthenia Gravis21
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets20
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale20
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial20
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management20
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy20
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update19
Plant-Derived Human Vaccines: Recent Developments19
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis19
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies18
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy18
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database18
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?18
Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence17
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience17
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe16
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project16
Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development15
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer15
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey15
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?15
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)15
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 14
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine13
Targeting IL-36 in Inflammatory Skin Diseases13
Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review13
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study13
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)12
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease12
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy12
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–202012
0.02544093132019